A director at Modine Manufacturing Co sold 25,761 shares at 134.774USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (G...
Tron Inc. Reports Record Second Quarter Financial Results -Over $111,000,000 in Shareholders’ Equity- Largest TRX Holdings of Any Public Company Winter Park, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tron Inc. (Nasdaq: TRON) (the “Company”), an innovation leader at the intersection of blockchain, entertainment and digital assets announced financial results for the fiscal quarter ending on June 30, 2025, in its Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on Friday. The Company reported net income of $1,467,855 for the three months ended June 30, 2025, compare...
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminentStrengthened cash position following a July At-The-Market (ATM) shares acquisition by a healthcare-dedicated institutional investor; June 30, 2025 proforma cash position of approximately $39 million FORT LEE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Ph...
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with intermittent dosing schedule; observed clinical activity warrants exploration of potential development opportunities in other cancer types NXP900 successfully completed a clinical...
Tron Inc. to Ring The Nasdaq Opening Bell on July 24, 2025 Winter Park, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Tron Inc. (Nasdaq: TRON) (the “Company”), an innovation leader at the intersection of blockchain, entertainment and digital assets, today announced it will ring the Nasdaq Stock Market Opening Bell on Thursday, July 24, 2025. The ceremony will be led by Justin Sun, Founder of the TRON Blockchain and Global Advisor to Tron Inc., live from the Nasdaq MarketSite in Times Square — heralding the Company’s bold transformation into next-generation technology and digital innovation....
Tron Inc. Announces Ticker Symbol Change to “TRON” on Nasdaq Winter Park, Florida, July 17, 2025 (GLOBE NEWSWIRE) -- Tron Inc. (Nasdaq: TRON) (“Tron” or the “Company”) today announced the official change of its Nasdaq ticker symbol from “SRM” to “TRON”, effective July 17, 2025. The Company’s CUSIP number (85237B101) will remain unchanged. This move reflects the Company’s broader strategic transformation and its commitment to aligning more closely with the Tron blockchain ecosystem, following the launch of its Tron-focused treasury strategy. “The Company’s ticker change to “TRON” reinfor...
SRM Rebrands to Tron Inc. and Adopts TRON as its New Ticker Symbol Winter Park, Florida, July 16, 2025 (GLOBE NEWSWIRE) -- SRM Entertainment, Inc. (Nasdaq: SRM) (“SRM” or the “Company”), today announced that it has changed its corporate name to Tron Inc., to align with its major transformation into a TRON (“TRX”) treasury strategy company. In addition to the name change, the Company will change its ticker to the symbol “TRON” on the Nasdaq Capital Market, effective July 17, 2025. After the name and ticker change, the Company’s CUSIP number of 85237B101 will remain the same. Since announc...
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs.The market leading epidermal growth factor receptor (“EGFR”) and anaplastic lymphoma kinase (“ALK”) inhibitors for the treatment of non-small cell lung cancer (“NSCLC”) are substrates of the Cytochrome P450 (“CYP”...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.